Results 341 to 350 of about 681,261 (380)

Plasminogen activators: A comparison

Vascular Pharmacology, 2006
Thrombolytic drugs play a crucial role in the management of patients with acute myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis, acute thrombosis of retinal vessel, extensive coronary emboli, and peripheral vascular thromboembolism.
M.R. Chaudhari, Dev B. Baruah, Rajendra N. Dash, Shivajirao S. Kadam   +3 more
openaire   +3 more sources

Plasminogen activation and cancer

Thrombosis and Haemostasis, 2005
SummaryBreakdown of the extracellular matrix is crucial for cancer invasion and metastasis. It is accomplished by the concerted action of several proteases, including the serine protease plasmin and a number of matrix metalloproteases. The activity of each of these proteases is regulated by an array of activators, inhibitors and cellular receptors ...
Danø, Keld, Behrendt, N., Hoyer-Hansen, G., Johnsen, Morten, Lund, L. R., Ploug, Michael, Nielsen, John Rømer   +6 more
openaire   +4 more sources

Studies on the kinetics of plasminogen activation by tissue plasminogen activator

Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1982
The steady-state rate of plasminogen activation by tissue plasminogen activator has been determined at various plasminogen concentrations. A plasmin substrate method similar to that presented by Christensen and Müllertz (Biochim. Biophys. Acta 480 (1977) 257-281) was used.
openaire   +3 more sources

Plasminogen Activators and Angiogenesis

1996
The formation of capillaries from preexisting blood vessels (angiogenesis) occurs in a variety of normal and pathological conditions, including organ development, would healing and tumor growth. Angiogenesis requires a strict temporal modulation of opposing cell functions: cell proliferation and migration, and extracellular matrix (ECM) degradation in ...
D. B. Rifkin, P. Mignatti
openaire   +3 more sources

Mechanisms of plasminogen activation

Journal of Internal Medicine, 1994
The fibrinolytic system consists of an inactive proenzyme, plasminogen, that is converted by plasminogen activators to the active enzyme, plasmin, that degrades fibrin. Two immunologically distinct plasminogen activators have been identified: tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA).
S. Thorsen, F. Bachmann, D C Rijken, H.R. Lijnen, H. Pannekoek, Desire Collen, V. Ellis   +6 more
openaire   +3 more sources

Tissue Plasminogen Activator

New England Journal of Medicine, 1988
TISSUE plasminogen activator (t-PA) is a naturally occurring protein that catalyzes the conversion of the inactive proenzyme plasminogen into the active serine protease plasmin.
John A. Oates, Alastair J.J. Wood, Joseph Loscalzo, Eugene Braunwald   +3 more
openaire   +3 more sources

Intrapleural use of tissue plasminogen activator and DNase in pleural infection.

New England Journal of Medicine, 2011
BACKGROUND More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcomes in an earlier, large, randomized trial.
Najib M. Rahman, Nicholas A. Maskell, A. West, R. Teoh, A. Arnold, C. Mackinlay, D. Peckham, Chris W.H. Davies, N. Ali, W. Kinnear, A. Bentley, B. Kahan, J. Wrightson, Helen E. Davies, Clare E. Hooper, Y.C. Gary Lee, E. Hedley, N. Crosthwaite, L. Choo, Emma J. Helm, F. V. Gleeson, Andrew J. Nunn, Robert J. O. Davies   +22 more
semanticscholar   +1 more source

Activation of Val442-plasminogen (mini-plasminogen) by urokinase, streptokinase and tissue plasminogen activator

Thrombosis Research, 1988
Glu-plasminogen (Glu-plg), Lys-plg and Val442-plg (mini-plg) were activated by urokinase (UK), streptokinase (SK) or tissue plasminogen activator (t-PA). Their activation rates were kinetically analyzed. UK activated Lys-plg with smaller Km and nearly identical Vmax as Glu-plg.
Yoshiaki Sugawara, Akikazu Takada, Yumiko Takada   +2 more
openaire   +2 more sources

Plasminogen activator inhibitors

Trends in Cardiovascular Medicine, 1991
Plasminogen activator inhibitors (PAIs) regulate plasminogen activation in normal and pathologic processes. Plasminogen activator inhibitor 1 (PAI-1) is the major physiologic inhibitor of both tissue-type and urokinase-type plasminogen activators. It is a highly regulated single-chain glycoprotein, whose overexpression in vivo impairs the fibrinolytic ...
David J. Loskutoff, Jacob Schneiderman
openaire   +3 more sources

Plasminogen activator and cancer

European Journal of Cancer and Clinical Oncology, 1984
Plasminogen activator is a protease which catalyses the conversion of the inactive plasminogen to the active plasmin. Most transformed cell lines and solid tumors produce elevated levels of plasminogen activator compared with nontransformed counterparts. This increased synthesis of plasminogen activator may play a role in tumorigenesis, cancer invasion
P. O'Grady, Michael J. Duffy
openaire   +3 more sources